123 related articles for article (PubMed ID: 11376561)
1. Expression of CYP2A6 in tumor cells augments cellular sensitivity to tegafur.
Murayama N; Sai K; Nakajima Y; Kaniwa N; Ozawa S; Ohno Y; Sawada J
Jpn J Cancer Res; 2001 May; 92(5):524-8. PubMed ID: 11376561
[TBL] [Abstract][Full Text] [Related]
2. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes.
Komatsu T; Yamazaki H; Shimada N; Nakajima M; Yokoi T
Drug Metab Dispos; 2000 Dec; 28(12):1457-63. PubMed ID: 11095583
[TBL] [Abstract][Full Text] [Related]
3. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro.
Ikeda K; Yoshisue K; Matsushima E; Nagayama S; Kobayashi K; Tyson CA; Chiba K; Kawaguchi Y
Clin Cancer Res; 2000 Nov; 6(11):4409-15. PubMed ID: 11106261
[TBL] [Abstract][Full Text] [Related]
4. A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur.
Daigo S; Takahashi Y; Fujieda M; Ariyoshi N; Yamazaki H; Koizumi W; Tanabe S; Saigenji K; Nagayama S; Ikeda K; Nishioka Y; Kamataki T
Pharmacogenetics; 2002 Jun; 12(4):299-306. PubMed ID: 12042667
[TBL] [Abstract][Full Text] [Related]
5. Cytosolic and microsomal activation of doxifluridine and tegafur to produce 5-fluorouracil in human liver.
Ozawa S; Hamada M; Murayama N; Nakajima Y; Kaniwa N; Matsumoto Y; Fukuoka M; Sawada J; Ohno Y
Cancer Chemother Pharmacol; 2002 Dec; 50(6):454-8. PubMed ID: 12451471
[TBL] [Abstract][Full Text] [Related]
6. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502).
Nunoya K; Yokoi T; Kimura K; Inoue K; Kodama T; Funayama M; Nagashima K; Funae Y; Green C; Kinoshita M; Kamataki T
Pharmacogenetics; 1998 Jun; 8(3):239-49. PubMed ID: 9682269
[TBL] [Abstract][Full Text] [Related]
7. Formation pathways of gamma-butyrolactone from the furan ring of tegafur during its conversion to 5-fluorouracil.
Yamamiya I; Yoshisue K; Matsushima E; Nagayama S
Drug Metab Dispos; 2010 Aug; 38(8):1267-76. PubMed ID: 20463005
[TBL] [Abstract][Full Text] [Related]
8. The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer.
Kaida Y; Inui N; Suda T; Nakamura H; Watanabe H; Chida K
Clin Pharmacol Ther; 2008 Apr; 83(4):589-94. PubMed ID: 18212800
[TBL] [Abstract][Full Text] [Related]
9. Effect of CYP2A6 genetic polymorphism on the metabolic conversion of tegafur to 5-fluorouracil and its enantioselectivity.
Yamamiya I; Yoshisue K; Ishii Y; Yamada H; Chiba M
Drug Metab Dispos; 2014 Sep; 42(9):1485-92. PubMed ID: 25002745
[TBL] [Abstract][Full Text] [Related]
10. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
Fujita K; Yamamoto W; Endo S; Endo H; Nagashima F; Ichikawa W; Tanaka R; Miya T; Araki K; Kodama K; Sunakawa Y; Narabayashi M; Miwa K; Ando Y; Akiyama Y; Kawara K; Kamataki T; Sasaki Y
Cancer Sci; 2008 May; 99(5):1049-54. PubMed ID: 18380793
[TBL] [Abstract][Full Text] [Related]
11. A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin.
Hadidi H; Zahlsen K; Idle JR; Cholerton S
Food Chem Toxicol; 1997 Sep; 35(9):903-7. PubMed ID: 9409631
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes.
Draper AJ; Madan A; Parkinson A
Arch Biochem Biophys; 1997 May; 341(1):47-61. PubMed ID: 9143352
[TBL] [Abstract][Full Text] [Related]
13. Determination of coumarin metabolism in Turkish population.
Cok I; Aygün Kocabaş N; Cholerton S; Karakaya AE; Sardaş S
Hum Exp Toxicol; 2001 Apr; 20(4):179-84. PubMed ID: 11393269
[TBL] [Abstract][Full Text] [Related]
14. Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations.
Shimada T; Yamazaki H; Guengerich FP
Xenobiotica; 1996 Apr; 26(4):395-403. PubMed ID: 9173680
[TBL] [Abstract][Full Text] [Related]
15. Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes.
Wang H; Bian T; Liu D; Jin T; Chen Y; Lin A; Chen C
Pharmacogenomics; 2011 Apr; 12(4):481-92. PubMed ID: 21521021
[TBL] [Abstract][Full Text] [Related]
16. Characteristic CYP2A6 genetic polymorphisms detected by TA cloning-based sequencing in Chinese digestive system cancer patients with S-1 based chemotherapy.
Fang WJ; Mou HB; Jin DZ; Zheng YL; Zhao P; Mao CY; Peng L; Huang MZ; Xu N
Oncol Rep; 2012 May; 27(5):1606-10. PubMed ID: 22322240
[TBL] [Abstract][Full Text] [Related]
17. Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes.
Nakajima M; Yamamoto T; Nunoya K; Yokoi T; Nagashima K; Inoue K; Funae Y; Shimada N; Kamataki T; Kuroiwa Y
J Pharmacol Exp Ther; 1996 May; 277(2):1010-5. PubMed ID: 8627511
[TBL] [Abstract][Full Text] [Related]
18. Evidence for cytochrome P450 2A6 and 3A4 as major catalysts for N'-nitrosonornicotine alpha-hydroxylation by human liver microsomes.
Patten CJ; Smith TJ; Friesen MJ; Tynes RE; Yang CS; Murphy SE
Carcinogenesis; 1997 Aug; 18(8):1623-30. PubMed ID: 9276639
[TBL] [Abstract][Full Text] [Related]
19. An inhibitory monoclonal antibody to human cytochrome P450 2A6 defines its role in the metabolism of coumarin, 7-ethoxycoumarin and 4-nitroanisole in human liver.
Sai Y; Yang TJ; Krausz KW; Gonzalez FJ; Gelboin HV
Pharmacogenetics; 1999 Apr; 9(2):229-37. PubMed ID: 10376770
[TBL] [Abstract][Full Text] [Related]
20. Spectrofluorometric analysis of CYP2A6-catalyzed coumarin 7-hydroxylation.
Waxman DJ; Chang TK
Methods Mol Biol; 1998; 107():111-6. PubMed ID: 14577218
[No Abstract] [Full Text] [Related]
[Next] [New Search]
